BeyondSpring Inc. (NASDAQ:BYSI) and uniQure N.V. (NASDAQ:QURE), both competing one another are Biotechnology companies. We will compare their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.
Earnings and Valuation
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
BeyondSpring Inc. | N/A | 0.00 | 56.85M | -2.54 | 0.00 |
uniQure N.V. | 11.28M | 196.89 | 83.30M | -2.69 | 0.00 |
Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies.
Profitability
Table 2 demonstrates the return on assets, net margins and return on equity of BeyondSpring Inc. and uniQure N.V.
Net Margins | Return on Equity | Return on Assets | |
BeyondSpring Inc. | 0.00% | -219.5% | -180.8% |
uniQure N.V. | -738.48% | -58.5% | -35.9% |
Liquidity
The Current Ratio and a Quick Ratio of BeyondSpring Inc. are 4.4 and 4.4. Competitively, uniQure N.V. has 7.6 and 7.6 for Current and Quick Ratio. uniQure N.V.’s better ability to pay short and long-term obligations than BeyondSpring Inc.
Analyst Recommendations
BeyondSpring Inc. and uniQure N.V. Recommendations and Ratings are available in the next table.
Sell Ratings | Hold Ratings | Buy Ratings | Rating Score | |
BeyondSpring Inc. | 0 | 0 | 0 | 0.00 |
uniQure N.V. | 0 | 0 | 7 | 3.00 |
Competitively the consensus price target of uniQure N.V. is $77.57, which is potential 30.04% upside.
Institutional and Insider Ownership
BeyondSpring Inc. and uniQure N.V. has shares owned by institutional investors as follows: 1.4% and 78.9%. Insiders owned 77.22% of BeyondSpring Inc. shares. Comparatively, insiders own roughly 2.2% of uniQure N.V.’s shares.
Performance
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
Performance (W) | Performance (M) | Performance (Q) | Performance (HY) | Performance (Y) | Performance (YTD) | |
BeyondSpring Inc. | 4.73% | 2.82% | -23.1% | -19.89% | -25.53% | -0.75% |
uniQure N.V. | 6.3% | 73.4% | 107.66% | 40.7% | 137.94% | 106.07% |
For the past year BeyondSpring Inc. had bearish trend while uniQure N.V. had bullish trend.
Summary
uniQure N.V. beats on 7 of the 10 factors BeyondSpring Inc.
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced NSCLC; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab. BeyondSpring Inc. was founded in 2010 and is headquartered in New York, New York.
uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The companyÂ’s principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington's disease. It also provides Glybera, a gene therapy product that has approved for the treatment of patients with lipoprotein lipase deficiency. The company has collaboration and license agreements with Bristol-Myers Squibb Company, 4D Molecular Therapeutics, Synpromics, and Chiesi Farmaceutici S.p.A. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
![](/free-report.png)
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.